Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Antineoplastons: The Controversy Continues

Antineoplastons: The Controversy Continues To the Editor. —Dr Green has presented a very cogent exposé of a troubling cancer therapy of unknown efficacy. Green analyzes in exquisite detail the biochemical and experimental results associated with antineoplastons, which would raise questions about their use in any clinical setting. It is one thing for new drugs under development to be studied in a classic phase I study, having gone through preclinical trials and deemed valid to merit clinical study after careful peer review. This apparently is not the case in the antineoplaston story, which raises serious concerns as to how this type of activity is allowed to continue. I have had personal experience with one patient, a 38-year-old woman, who developed recurrent rectal cancer involving the lower pelvis. This patient's cancer had progressed in spite of treatment with radiation and chemotherapy and was looking for alternative therapy. She found her way to the Burzynski Clinic where http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Antineoplastons: The Controversy Continues

Wanebo, Harold J.
JAMA , Volume 269 (4) – Jan 27, 1993
Download PDF
1 page

Antineoplastons: The Controversy Continues

Abstract



To the Editor.
—Dr Green has presented a very cogent exposé of a troubling cancer therapy of unknown efficacy.
Green analyzes in exquisite detail the biochemical and experimental results associated with antineoplastons, which would raise questions about their use in any clinical setting. It is one thing for new drugs under development to be studied in a classic phase I study, having gone through preclinical trials and deemed valid to merit clinical study after careful peer...
Loading next page...
 
/lp/american-medical-association/antineoplastons-the-controversy-continues-n6CCUkaq1v

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright © 1993 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1993.03500040041029
Publisher site
See Article on Publisher Site

Abstract

To the Editor. —Dr Green has presented a very cogent exposé of a troubling cancer therapy of unknown efficacy. Green analyzes in exquisite detail the biochemical and experimental results associated with antineoplastons, which would raise questions about their use in any clinical setting. It is one thing for new drugs under development to be studied in a classic phase I study, having gone through preclinical trials and deemed valid to merit clinical study after careful peer review. This apparently is not the case in the antineoplaston story, which raises serious concerns as to how this type of activity is allowed to continue. I have had personal experience with one patient, a 38-year-old woman, who developed recurrent rectal cancer involving the lower pelvis. This patient's cancer had progressed in spite of treatment with radiation and chemotherapy and was looking for alternative therapy. She found her way to the Burzynski Clinic where

Journal

JAMA – American Medical Association

Published: Jan 27, 1993

There are no references for this article.